Treatment with high-dose aducanumabshows less clinical decline across individual items or domains of cognition, function, and behaviour compared with placebo in patients with early symptomatic Alzheimer’s disease (AD), according to the EMERGE* study presented at AAIC 2021.
Transgender adults had a higher likelihood of experiencing subjective cognitive decline (SCD) and SCD-related functional limitations compared with their cisgender counterparts, according to a study presented at AAIC 2021.
Midlife adults aged between 50 and 70 years who reported a short sleep duration of ≤6 hours/night had an increased risk of developing dementia later in life, according to a study presented at AAIC 2021.
Two studies presented at AAIC 2021 showed a potential neuroprotective effect of a ketogenic supplement or diet: In one study, consumption of a keto drink was associated with improvements in dorsal attention network (DAN) functional connectivity in mild cognitive impairment (MCI). Another study showed the keto diet’s potential to improve aberrant default mode network (DMN) connectivity patterns in adults at risk for Alzheimer’s disease (AD).
In patients with neurodegenerative and/or neurovascular disease (NDD) and dementia-related psychosis (DRP), concomitant antidementia medications (cADMs) used alongside the selective serotonin receptor modulating agent pimavanserin did not adversely impact its safety and pharmacokinetic (PK) profile, according to data presented at AAIC 2021.